Antibody-drug conjugates are the fastest-growing class in oncology. DrugConjugate brings computational linker-payload optimization and organ-chip toxicity screening to ADC development.
Computational models predict cleavage kinetics, DAR optimization, and bystander effects across conjugation chemistries - before synthesis.
Test hepatotoxicity, nephrotoxicity, and off-target payload release on human tissue chips. No animal models required for early-stage decisions.
Vascularized tumor-on-chip models with immune cell co-culture let you test ADC efficacy in human-relevant tumor stroma conditions.
This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.
Submit your inquiry below and we'll respond within 24 hours.